Condition
Relapsed/Refractory Multiple Myeloma (RRMM) clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Relapsed/Refractory Multiple Myeloma (RRMM) clinical trials that are recruiting, at sites in 13 countries (most in China (2), Denmark (1), France (1)). By phase: Early Phase 1 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 13Countries
Newest Relapsed/Refractory Multiple Myeloma (RRMM) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Linvoseltamab with pre-dose Tocilizumab to reduce CRS in adults with relapsed/refractory multiple myeloma | Phase 4 | Los Angeles, California and 6 other locations | Recruiting | May 27, 2026 |
| Epunamin plus DECP for relapsed or refractory multiple myeloma | — | Taiyuan, Shanxi | Recruiting | Mar 27, 2026 |
| IASO206 injection for relapsed or refractory multiple myeloma | Early Phase 1 | Tianjin | Recruiting | Jan 7, 2026 |
| Examining outcomes in patients with relapsed/refractory multiple myeloma treated with T-cell redirectors | — | Aalborg and 67 other locations | Recruiting | Feb 29, 2024 |
All recruiting trials (4)
-
Linvoseltamab with pre-dose Tocilizumab to reduce CRS in adults with relapsed/refractory multiple myeloma
This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome in adults with relapsed/refractory multiple myeloma who have had at least four prior therapies.
-
Epunamin plus DECP for relapsed or refractory multiple myeloma
This will test whether adding Epunamin to a DECP chemotherapy regimen helps people with relapsed or refractory multiple myeloma have better treatment responses.
-
IASO206 injection for relapsed or refractory multiple myeloma
A single-arm early study is testing IASO206 injection to see if it is safe and tolerable for adults with relapsed or refractory multiple myeloma who have tried at least two prior therapies.
-
Examining outcomes in patients with relapsed/refractory multiple myeloma treated with T-cell redirectors
This study looks at how well T-cell redirectors like teclistamab and talquetamab work for people with relapsed or refractory multiple myeloma who have been treated outside of clinical trials.
Related topics
Quick answers
How many Relapsed/Refractory Multiple Myeloma (RRMM) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 13 countries. The most sites are in China (2 trials), Denmark (1 trial), France (1 trial), Germany (1 trial), Greece (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.